

Clinical dosage of lidocaine does not impact the biomedical outcome of sepsis-induced acute respiratory distress syndrome in a porcine model

René Rissel, Christian Moellmann, Victoria Albertsmeier, Miriam Renz, Robert Ruemmler, Jens Kamuf, Erik K. Hartmann and Alexander Ziebart

Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg-University, Mainz, Germany

ABSTRACT

Background: Sepsis is a common disease in intensive care units worldwide, which is associated with high morbidity and mortality. This process is often associated with multiple organ failure including acute lung injury. Although massive research efforts have been made for decades, there is no specific therapy for sepsis to date. Early and best treatment is crucial. Lidocaine is a common local anesthetic and used worldwide. It blocks the fast voltage-gated sodium (Na^+) channels in the neuronal cell membrane responsible for signal propagation. Recent studies show that lidocaine administered intravenously improves pulmonary function and protects pulmonary tissue in pigs under hemorrhagic shock, sepsis and under pulmonary surgery. The aim of this study is to show that lidocaine inhalative induces equivalent effects as lidocaine intravenously in pigs in a lipopolysaccharide (LPS)-induced sepsis with acute lung injury.

Methods: After approval of the local State and Institutional Animal Care Committee, to induce the septic inflammatory response a continuous infusion of lipopolysaccharide (LPS) was administered to the pigs in deep anesthesia. Following induction and stabilisation of sepsis, the study medication was randomly assigned to one of three groups: (1) lidocaine intravenously, (2) lidocaine per inhalation and (3) sham group. All animals were monitored for 8 h using advanced and extended cardiorespiratory monitoring. Postmortem assessment included pulmonary mRNA expression of mediators of early inflammatory response (IL-6 & TNF-alpha), wet-to-dry ratio and lung histology.

Results: Acute respiratory distress syndrome (ARDS) was successfully induced after sepsis-induction with LPS in all three groups measured by a significant decrease in the $\text{PaO}_2/\text{FiO}_2$ ratio. Further, septic hemodynamic alterations were seen in all three groups. Leucocytes and platelets dropped statistically over time due to septic alterations in all groups. The wet-to-dry ratio and the lung histology showed no differences between the groups. Additionally, the pulmonary mRNA expression of the inflammatory mediators IL-6 and TNF-alpha showed no significant changes between the groups. The proposed anti-inflammatory and lung protective effects of lidocaine in sepsis-induced acute lung injury could not be proven in this study.

Submitted 26 March 2023

Accepted 18 July 2023

Published 21 August 2023

Corresponding author

René Rissel,

Rene.Rissel@unimedizin-mainz.de

Academic editor

Nagendran Tharmalingam

Additional Information and
Declarations can be found on
page 13

DOI 10.7717/peerj.15875

© Copyright

2023 Rissel et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Anesthesiology and Pain Management, Emergency and Critical Care, Respiratory Medicine, Translational Medicine

Keywords ARDS, Lidocaine, Inflammation, Animal model, Sepsis

INTRODUCTION

Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, resulting in organ dysfunction ([Singer et al., 2016](#)). It is a common and severe disease in critical care medicine worldwide and is associated with high morbidity and mortality rates, often leading to multiple organ failure, including acute lung injury ([Alberti et al., 2002](#)). Despite decades of research, there is currently no specific therapy for sepsis, underscoring the need for early and optimal treatment. The latest guidelines from the Surviving Sepsis Campaign emphasize the individual nature of sepsis and highlight various general therapy concepts ([Evans et al., 2021](#)).

Given the urgent need for effective treatments for sepsis, various medical concepts are being researched to identify breakthrough therapies. One promising approach is the use of lidocaine. Lidocaine is a commonly used local anesthetic that blocks fast voltage-gated sodium (Na^+) channels in neuronal cell membranes, which are responsible for signal propagation. Lidocaine also acts as an anti-arrhythmic agent by blocking the voltage-gated Na^+ channels in the heart muscle ([Beaussier et al., 2018](#)). However, lidocaine may cause side effects such as sleepiness, confusion, cardiac arrhythmia, and vomiting ([Caracas et al., 2009](#)). Recent studies have shown that intravenous administration of lidocaine can improve pulmonary function and protect pulmonary tissue in pigs with hemorrhagic shock, sepsis, or undergoing pulmonary surgery ([Romera et al., 2021; Kodama et al., 2000; Berger et al., 2014](#)). Lidocaine has also been shown to attenuate acute respiratory distress syndrome (ARDS) and increase anti-inflammatory effects. Although the anti-inflammatory effects of lidocaine have been observed with intravenous administration, recent studies have suggested that nebulized lidocaine may also have the potential to prevent airway inflammation ([Serra et al., 2012](#)). However, scientific studies on this effect remain limited, and a direct comparison of the effectiveness of both administration methods in the context of sepsis has yet to be conducted.

The objective of this study is to investigate whether the inhalation of lidocaine can produce effects comparable to those achieved with intravenous administration in a pig model of lipopolysaccharide (LPS)-induced sepsis and acute lung injury. This study aims to fill the existing knowledge gap and contribute to the development of more effective therapies for sepsis.

MATERIALS AND METHODS

The protocol used in this study was approved by the State and Institutional Animal Care Committee (Rhineland-Palatinate, Koblenz, Germany; ID G16-1-015) in accordance with the ARRIVE guidelines ([Kilkenny et al., 2010](#)). The research involved 32 pigs ($30 \pm 2.5 \text{ kg}$) acquired from a local farmer and transported to the laboratory under sedation with azaperone and midazolam administered intramuscularly.

Anesthesia & instrumentation

Anesthesia was induced and maintained through continuous infusion of propofol and fentanyl, with atracurium used intravenously solely to facilitate endotracheal intubation. Basic monitoring, including pulse oximetry (Radical 7; Masimo, Irvine, CA, USA) and invasive blood pressure (S/5, GE-Datex-Ohmeda; Chalfont, St. Giles, United Kingdom), was performed. Animals were ventilated using pressure-controlled ventilation-volume guaranteed mode (PCV-VG) (Engström Carestation; GE healthcare, Chalfont, St Giles, Buckinghamshire, UK) with a tidal volume of 6–8 ml kg⁻¹, a positive end-expiratory pressure (PEEP) of 5 mbar, fraction of inspired oxygen (FiO₂) of 0.4, and respiratory rate adjusted to the end-tidal CO₂.

Seldinger's technique was employed for femoral vascular access after ultrasound-guided puncture to place a central venous line, a venous introducer for a pulmonary artery catheter, and an arterial introducer for a pulse contour cardiac output catheter (PiCCO; Pulsion Medical, Munich, Germany). The data from all devices were continuously monitored and stored. Balanced electrolyte fluid (BEL, Sterofundin; Braun, Melsungen, Germany) was administered at a rate of 5 ml⁻¹ kg⁻¹.

Sepsis induction

To induce a septic inflammatory response, a continuous infusion of LPS (*E. coli* Serotype O111:B4; Sigma-Aldrich, Buchs, Switzerland) was administered at a high-dose induction of 150 µg kg⁻¹ h⁻¹ for 1 h, followed by a maintenance dosage of 15 µg kg⁻¹ h⁻¹ throughout the experiment. To prevent the risk of implausible results and lung injury caused by severe hypoxemia or hypercapnia during LPS infusion, an intervention scheme was established. This scheme was based on the ARDS Network PEEP/FiO₂ tables, and ventilation parameters were adjusted when the peripheral oxygen saturation dropped below 92% for 5 min.

Study protocol

Following induction and stabilisation of sepsis, the study medication was randomly assigned to one of three groups by impartial observers who were blinded to the study design.

- 1) Lidocaine intravenous (*n* = 8): 2 mg kg⁻¹ h⁻¹ for 1 h, followed by 1 mg kg⁻¹ h⁻¹
- 2) Lidocaine inhalative (*n* = 8): 2 mg kg⁻¹ h⁻¹ for 1 h, followed by 1 mg kg⁻¹ h⁻¹
- 3) Sham group (*n* = 8): NaCl 0.9%, 5 ml/h i.v. continuously.

The dosage is based on standard dosages as used for intraoperative lidocaine infusion in humans (Dunn & Durieux, 2017). The inhalation treatment group received lidocaine via a clinical nebulizer (Aeroneb ProX; Aerogen Ltd, Galway, Ireland). Blood samples were taken at baseline (BLH), 4 h (T4), and 8 h (T8) after sepsis induction. Blood gas analysis, cardiac output, and spirometry were measured at baseline and hourly after sepsis induction. Bronchial lavage was performed 8 h after sepsis induction at the lower left lobe. To maintain a mean arterial pressure above 60 mmHg, noradrenaline was administered. Glucose 40% was administered to maintain a blood glucose level above 70 mg/dL, and

body temperature was measured by the PiCCO catheter, with normothermia maintained by body surface warming. The respiratory rate was adjusted to maintain an arterial pCO_2 of 35–45 mmHg, and F_1O_2 and PEEP were adjusted to maintain $\text{SpO}_2 > 93\%$ according to the ARDS Network Trial.

Post mortem analysis

The experiment was ended under deep general anesthesia with an injection of 200 mg of propofol and 40 mmol of potassium chloride. The lung was extracted post-mortem in one piece and exsanguinated. The post-mortem pulmonary expressions of inflammatory markers (IL-6 and TNF-alpha) were determined in cryopreserved lung samples from the right lower lobe for mRNA analysis by real-time polymerase chain reaction (rt-PCR; Lightcycler 480 PCR System; Roche Applied Science, Penzberg, Germany). The mRNA expression was normalized to peptidylprolyl isomerase A. Lung damage was evaluated using a standardized scoring system, and the wet-to-dry ratio was determined using a predefined slice of the right upper lobe ([Spieth et al., 2012](#); [Ziebart et al., 2014](#)).

Statistics

The data are presented as mean \pm standard deviation. Statistical analyses were conducted using SigmaPlot 12.5 (Systat Software Inc, San Jose, CA, USA). The Wilcoxon test was employed to compare values before and after the intervention, whereas the two-way ANOVA on ranks followed by the Holm-Sidak method was utilized to assess intergroup differences over time. The Spearman coefficient was used to evaluate correlations. P -values less than 0.05 were considered statistically significant.

RESULTS

In this study, 24 animals from three groups survived the observation period of 8 h after sepsis induction, while eight animals did not survive ($n = 3$ for sham and lidocaine i.v.; $n = 2$ for lidocaine p.i.).

Hemodynamics

Mean arterial pressure (MAP) and mean arterial pulmonary pressure (mPAP) were stable across all groups throughout the experiment, as shown in [Table 1](#). Similar findings were observed for central venous pressure (CVP) and pulmonary capillary wedge pressure (PCWP) ([Table 1](#)). At baseline (BLH) and T0, heart rate (HR) and cardiac output (CO) values were comparable across all groups. However, at T4 and T8, both HR and CO values increased significantly in all groups compared to BLH, without any intergroup differences (CO: $p < 0.006/p < 0.001$ for T4/T8 vs. BLH for lidocaine i.v., $p < 0.001$ for T8 vs. BLH for lidocaine p.i., $p < 0.049$ for T8 vs. BLH for sham; heart rate: $p < 0.001$ for T4/T8 vs. BLH in all groups; [Figs. 1](#) and [2](#)). Extravascular lung water index (EVLWI) and global end-diastolic volume index (GEDVI) showed no significant changes throughout the experiment ([Table 1](#)).

Table 1 Hemodynamic parameters.

Parameter	Group	BLH	T0	T4	T8
		Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
MAP (mmHg)	Lidocaine p.i.	66 (8)	69 (7)	64 (5)	62 (3)
	Lidocaine i.v.	67 (8)	67 (6)	60 (4)	61 (5)
	Sham	63 (7)	71 (8)	65 (5)	60 (7)
mPAP (mmHg)	Lidocaine p.i.	8 (1)	9 (2)	14 (4)	15 (3)
	Lidocaine i.v.	7 (1)	8 (1)	10 (3)	12 (2)
	Sham	8 (1)	9 (1)	11 (2)	14 (3)
CVP (mmHg)	Lidocaine p.i.	5 (1)	7 (2)	7 (2)	9 (3)
	Lidocaine i.v.	6 (2)	8 (1)	9 (1)	10 (2)
	Sham	6 (2)	9 (2)	9 (3)	10 (3)
CO (l min ⁻¹)	Lidocaine p.i.	3.34 (0.4)	3.66 (0.5)	4.39 (1.1)	5.0 (1.1)*
	Lidocaine i.v.	3.53 (0.4)	3.62 (0.7)	4.92 (0.9)*	6.14 (1.0)*
	Sham	3.15 (0.5)	3.31 (0.5)	4.81 (1.1)*	5.5 (1.4)*
PCWP (mmHg)	Lidocaine p.i.	8 (2)	9 (2)	7 (3)	5 (4)
	Lidocaine i.v.	10 (2)	10 (2)	9 (3)	10 (4)
	Sham	7 (2)	11 (2)	9 (2)	10 (3)
GEDVI (ml m ⁻²)	Lidocaine p.i.	486 (97)	519 (116)	502 (105)	496 (96)
	Lidocaine i.v.	524 (73)	565 (138)	521 (90)	568 (136)
	Sham	490 (75)	523 (96)	503 (105)	535 (115)
EVLWI (ml kg ⁻¹)	Lidocaine p.i.	11 (2)	12 (2)	15 (2)	16 (3)
	Lidocaine i.v.	11 (2)	12 (4)	15 (3)	16 (2)
	Sham	11 (2)	12 (1)	15 (2)	15 (2)

Notes:* $p < 0.05$ vs. baseline value.

MAP, mean arterial pressure; HR, heart rate; mPAP, mean arterial pulmonary pressure; CO, cardiac output; PCWP, pulmonary capillary wedge pressure; GEDVI, global enddiastolic volumen index; EVLWI, entdiastolic lung water index; CVP, central venous pressure.

Respiratory

The oxygen saturation (SpO_2) and the fraction of inspired oxygen (FiO_2) showed no differences (Table 2). At BLH and T0, the oxygen index ($\text{PaO}_2/\text{FiO}_2$) did not differ (Fig. 3). A significant drop for the $\text{PaO}_2/\text{FiO}_2$ ratio was observed at T4 and T8 in all groups ($p < 0.001$ for T4/T8 vs. BLH in all groups; Fig. 3). Contrary, the minute volume (MV) increased statistically over the time in all groups without any intergroup differences ($p < 0.001$ for T4/T8 vs. BLH in all groups; Table 2). Similar results were seen for the peak inspiratory pressure (Ppeak) and mean airway pressure (Pmean), both increased significant over time in all three groups (Ppeak: $p < 0.001$ for T4/T8 vs. BLH for all groups; Pmean: $p < 0.024$ / $p < 0.001$ for T4/T8 vs. BLH for sham, $p < 0.001$ for T4/T8 vs. BLH for lidocaine i.v./p.i.; Table 2). The positive endexpiratory pressure (PEEP) showed no differences at baseline and raised statistically in all groups at T8 compared to baseline ($p < 0.032$ T8 vs. BLH for sham, $p < 0.001$ T8 vs. BLH for lidocaine p.i., $p < 0.04$ for T8 vs. BLH for lidocaine i.v.; Table 2). In the lidocaine intravenous group, this increase was already at T4 and remained elevated ($p < 0.028$ for T4 vs. BLH; Table 2). The functional




Figure 1 Cardiac output. * $p < 0.05$ for all groups compared to BLH. BLH, baseline; T_x, Timepoints.
Full-size DOI: 10.7717/peerj.15875/fig-1




Figure 2 Heart rate. * $p < 0.05$ for all groups compared to BLH. BLH, baseline; T_x, Timepoints.
Full-size DOI: 10.7717/peerj.15875/fig-2

Table 2 Spirometry parameters.

Parameter	Group	BLH	T0	T4	T8
		Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
SpO ₂ (%)	Lidocaine p.i.	98 (1.5)	98 (3)	96 (2)	95 (2)
	Lidocaine i.v.	98 (1)	98 (1)	97 (2)	96 (2)
	Sham	99 (1)	98 (2)	97 (3)	95 (3)
FiO ₂ (%)	Lidocaine p.i.	0.4 (0)	0.4 (0)	0.4 (0.1)	0.5 (0.1)
	Lidocaine i.v.	0.4 (0)	0.4 (0)	0.4 (0.1)	0.5 (0.1)
	Sham	0.4 (0)	0.4 (0)	0.4 (0.1)	0.5 (0.1)
FRC (ml)	Lidocaine p.i.	575 (190)	520 (172)	308 (191)	543 (202)
	Lidocaine i.v.	580 (170)	570 (165)	487 (151)	423 (107)
	Sham	574 (154)	515 (122)	440 (131)	393 (178)*
MV (l min ⁻¹)	Lidocaine p.i.	6.4 (1.0)	6.6 (1.0)	7.4 (1.0)*	8.4 (1.0)*
	Lidocaine i.v.	6.2 (1.0)	6.6 (0.5)	7.4 (0.5)*	8.1 (0.5)*
	Sham	6.3 (0.5)	6.4 (0.5)	7.3 (1.0)*	7.8 (1.0)*
Ppeak (mbar)	Lidocaine p.i.	15 (2)	19 (4)	29 (7)*	30 (5)*
	Lidocaine i.v.	14 (1)	16 (2)	24 (6)*	26 (7)*
	Sham	14 (2)	17 (3)	24 (4)*	28 (5)*
Pmean (mbar)	Lidocaine p.i.	8 (1)	9 (2)	14 (4)*	15 (3)*
	Lidocaine i.v.	8 (1)	9 (1)	13 (4)*	13 (4)*
	Sham	8 (1)	9 (1)	11 (2)*	14 (3)*
PEEP (cm H ₂ O)	Lidocaine p.i.	5 (0)	5 (0)	6 (3)	9 (2)*
	Lidocaine i.v.	5 (0)	5 (0)	7 (3)*	8 (3)*
	Sham	5 (0)	5 (0)	5 (2)	8 (3)*

Notes:* $p < 0.05$ vs. baseline value.SpO₂, oxygen saturation; PaO₂, arterial oxygen; FiO₂, fraction of inspired oxygen; PaO₂/FiO₂, oxygen index; FRC, functional residual capacity; MV, minute volume; Ppeak, peak inspiratory pressure; Pmean, mean airway pressure; PEEP, positive end-expiratory pressure.

residual capacity (FRC) showed only a decrease at T8 in the sham group with statistical relevance ($p < 0.037$ T8 vs. BLH for lidocaine i.v.; **Table 2**).

Laboratory

Throughout the experiment, there were no significant differences in measured lactate and potassium values among all groups (**Table 3**). Similarly, pH values were comparable between the baseline measurement (BLH) and time point T0 for all groups (**Table 3**). However, at time points T4 and T8, all groups showed a significant decrease in pH compared to BLH, with no intergroup differences observed ($p < 0.001$ for T4/T8 vs. BLH for all groups; **Table 3**). The base excess (BE) showed a similar trend, with all groups exhibiting a significant decrease at T4 and T8 compared to BLH ($p < 0.001$ for T4/T8 vs. BLH for all groups; **Table 3**). The arterial oxygen pressure (PaO₂) decreased over time in all three groups, with statistically significant differences observed at T4 and T8 ($p < 0.001$ for T4/T8 vs. BLH for all groups; **Table 3**). In contrast, the arterial carbon dioxide pressure (PaCO₂) increased over time for all groups ($p < 0.002$ / $p < 0.001$ for T4/T8 vs. BLH for




Figure 3 $\text{PaO}_2/\text{FiO}_2$ ratio. * $p < 0.05$ for all groups compared to BLH. BLH, baseline; T_x , Timepoints.

Full-size DOI: 10.7717/peerj.15875/fig-3

Table 3 Blood gas analysis.

Parameter	Group	BLH	T0	T4	T8
		Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
pH	Lidocaine p.i.	7.50 (0.02)	7.47 (0.04)	7.41 (0.07)*	7.37 (0.05)*
	Lidocaine i.v.	7.53 (0.04)	7.48 (0.01)	7.38 (0.06)*	7.40 (0.04)*
	Sham	7.46 (0.07)	7.47 (0.03)	7.39 (0.09)*	7.38 (0.09)*
BE (mmol l ⁻¹)	Lidocaine p.i.	4.3 (2.1)	4.9 (1.4)	1.8 (1.9)*	1.3 (2.7)*
	Lidocaine i.v.	5.3 (2.4)	4.6 (1.9)	0.7 (2.6)*	1.4 (1.6)*
	Sham	3.0 (2.9)	3.8 (1.9)	-1.6 (4.3)*	1.3 (4.1)*
paCO ₂ (mmHg)	Lidocaine p.i.	35 (3)	39 (3)	44 (7)*	49 (7)*
	Lidocaine i.v.	35 (2)	37 (2)	43 (6)*	44 (5)*
	Sham	37 (4)	38 (1)	42 (6)*	46 (6)*
PaO ₂ (mmHg)	Lidocaine p.i.	204 (18)	178 (37)	93 (25)*	76 (18)*
	Lidocaine i.v.	215 (21)	199 (30)	126 (30)*	79 (29)*
	Sham	202 (18)	186 (22)	101 (24)*	81 (12)*
Potassium (mmol l ⁻¹)	Lidocaine p.i.	3.8 (0.3)	4.1 (0.4)	4.8 (0.4)	4.9 (0.6)
	Lidocaine i.v.	3.8 (0.2)	3.9 (0.3)	4.2 (0.3)	4.5 (0.5)
	Sham	3.8 (0.4)	4.1 (0.3)	4.3 (0.5)	4.6 (0.6)
Lactate (mmol l ⁻¹)	Lidocaine p.i.	1.4 (1.2)	1.6 (0.5)	2.8 (1.0)	1.5 (1.0)
	Lidocaine i.v.	0.9 (0.5)	1.5 (0.6)	2.8 (2.3)	1.9 (5.1)
	Sham	1.0 (0.3)	1.4 (0.6)	2.6 (0.8)	1.7 (0.8)

Notes:

* $p < 0.05$ vs. baseline value.

BE, base excess; PaCO₂, arterial carbon dioxide; PaO₂, arterial oxygen.

Table 4 Laboratory parameters.

Parameter	Group	BLH	T4	T8
		Mean (SD)	Mean (SD)	Mean (SD)
Leucocytes (%)	Lidocaine p.i.	17.10 (4.95)	1.59 (0.66)*	2.99 (1.65)*
	Lidocaine i.v.	13.41 (3.74)	1.14 (0.19)*	2.38 (1.09)*
	Sham	12.65 (4.08)	1.23 (0.47)*	2.03 (0.47)*
Hemoglobin (%)	Lidocaine p.i.	9.27 (0.53)	9.61 (0.64)	9.22 (0.71)
	Lidocaine i.v.	9.22 (0.58)	9.75 (0.58)	9.58 (0.89)
	Sham	9.63 (0.56)	10.02 (0.89)	9.30 (1.08)

Note:* $p < 0.05$ vs. baseline value.

lidocaine p.i.; $p < 0.004/p < 0.006$ for T4/T8 for sham; $p < 0.04/p < 0.003$ T4/T8 vs. BLH for lidocaine i.v.; **Table 3**). At time points T4 and T8, all groups showed a significant decrease in leucocyte count compared to the baseline measurement (BLH), with no significant intergroup differences observed ($p < 0.008/p < 0.006$ for T4/T8 vs. BLH for sham; $p < 0.001$ for T4/T8 vs. BLH for lidocaine i.v./p.i.; **Table 4**). Similar results were observed for thrombocyte count (**Fig. 4**). Hemoglobin levels remained stable over time and showed no statistically significant differences between groups ($p < 0.001$ for T4/T8 vs. BLH for all groups; **Table 4**).

Post mortem analysis

The wet-to-dry ratio exhibited no significant differences between groups (6.21 ± 1.03 for p.i. vs. 6.77 ± 1.57 for i.v. vs. 5.19 ± 0.80 for sham). Further, the lung damage score confirmed the lung damage but showed no differences between the groups (**Fig. 5**, exemplary lung tissue from one lidocaine i.v. pig). The mRNA expression of TNF-alpha and IL-6 in lung tissue was lower in both the p.i. and i.v. groups compared to the sham group, although this difference was not statistically significant (**Fig. 6**).

DISCUSSION

In this study, the proposed anti-inflammatory effects of the local anesthetic lidocaine in a sepsis induced ARDS in pigs were investigated. Lidocaine was administered in two ways: intravenous and per inhalation. The sepsis induced ARDS model using LPS was chosen due to its high reproducibility and suitability in pigs ([Matute-Bello, Frevert & Martin, 2008](#); [Matute-Bello et al., 2011](#)). The model produced common septic-like hemodynamic alterations such as an increase in heart rate and elevated cardiac output in the hyperdynamic septic state. Additionally, a significant decrease in leucocytes and thrombocytes, as required in the sepsis-related organ failure assessment (SOFA) score to screen for sepsis, was observed ([Vincent et al., 1996](#)). The present experiment also demonstrated sepsis-induced pulmonary functional impairment. The methods utilized in this study have been previously employed to investigate and demonstrate diverse aspects of sepsis, including but not limited to the evaluation of the lung-protective and




Figure 4 Thrombocytes. * $p < 0.05$ for all groups compared to BLH. BLH, baseline; T_x, Timepoints.

[Full-size](#) DOI: 10.7717/peerj.15875/fig-4




Figure 5 Lung tissue. Exemplary histopathological lung tissue (lidocaine i.v.). 1: alveolar oedema. 2: alveolar rupture. 3: hemorrhage.

[Full-size](#) DOI: 10.7717/peerj.15875/fig-5

anti-inflammatory properties of novel inhalation agents, the analysis of the effects of distinct ventilation protocols, and the assessment of the impact of sepsis on the endothelial glycocalyx ([Ziebart et al., 2014](#); [Thomas et al., 2022](#); [Hartmann et al., 2014](#)).




Figure 6 Pulmonary mRNA expression of TNF-alpha and IL-6. PPIA, Peptidylprolyl Isomerase A.

[Full-size](#) DOI: [10.7717/peerj.15875/fig-6](https://doi.org/10.7717/peerj.15875/fig-6)

Intravenous administration of lidocaine has been shown to suppress the inflammatory response in a rat model of acute lung injury induced by cecal ligation and puncture (CLP) ([Zhang et al., 2017](#)). The continuous intravenous administration of lidocaine is common in human medicine and offers some advantages. Despite stable hemodynamic conditions, the continuous administration of lidocaine is associated with increased and stable blood lidocaine levels compared to the bolus injection ([Kintzel, Knol & Roe, 2019](#)). Additionally, low concentrations of lidocaine have been demonstrated to reduce anoxic damage. The therapeutic effects of lidocaine are mediated through the receptor for advanced glycation end products (RAGE) and the downregulation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and mitogen-activated protein kinase (MAPK) signaling pathways ([Zhang et al., 2017](#); [Ma, Yan & He, 2022](#)). These pathways have been identified as key regulators for the release of various inflammatory mediators, such as tumor necrosis factor alpha (TNF- α) and interleukin-6 (IL-6), which play a vital role in the pathogenesis of acute lung injury ([Bos & Ware, 2022](#)).

Nebulized administration of lidocaine has been observed to cause pathophysiological reactions in the lungs, such as peribronchial eosinophil and neutrophil infiltration, subepithelial fibrosis, increased collagen and mucus content, matrix metalloproteinase-9 activity, and elevated levels of interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), and eotaxin-1 ([Serra et al., 2012](#)). These effects may be attributed to the local anesthetic's anti-inflammatory properties. Additionally, lidocaine has been suggested as a potential therapy for Coronavirus Disease-2019 (COVID-19) due to its capacity to reduce cytokine levels, protect the lungs, and lower morbidity and mortality ([Ali & El-Mallakh, 2020](#)).

Unfortunately, the study did not demonstrate any statistically significant differences in the mRNA expression of TNF-alpha and IL-6 in lung tissue. Moreover, no significant decrease in systemic inflammatory parameters, such as lactate levels, was observed.

One possible explanation is that the duration of our experiment, which was set at 8 h, may have been too short to observe significant changes. In contrast, the aforementioned study had a longer duration of 12 h, possibly allowing for a more sensitive analysis of the transcriptional regulation of inflammatory markers (Chen *et al.*, 2018). Additionally, it should be noted that Chen *et al.* (2018) measured the concentrations of mediators in the bronchoalveolar lavage fluid (BALF) rather than in lung tissue, and there is a lack of reliable and comparable data on different concentrations in both compartments in the literature. Furthermore, the dosage of lidocaine used in their study was higher, up to 5 mg kg⁻¹. Such high dosages are unusual when lidocaine is used in human medicine. Therefore, in the present study, we oriented ourselves to a dosage that has been safely and well investigated in the context of intravenous administration in the perioperative setting in humans (Dunn & Durieux, 2017). Since we could not prove the results shown by Chen *et al.* (2018) in our “low-dose study”, this underlines the assumption that the reported results are dose-dependent.

The present study did not observe the previously reported reduction in vascular permeability and inhibition of edema formation after intravenous and systemic administration of lidocaine (Caracas *et al.*, 2009). In all groups, a slight increase in EVLWI was measured, possibly due to septic rupture of the alveolo-capillary unit, which contributed to the restriction of lung function, as indicated by the decreased PaO₂/FiO₂ ratio. This non-cardiogenic edema seen in ARDS is an independent risk factor for mortality (Jozwiak *et al.*, 2013). Tight junctions, gap junctions, and adherens junctions are critical proteins that ensure pulmonary homeostasis and transcapillary fluid management. Inflammation and oxidative stress can target all of them, resulting in apoptosis mediated by an upregulation of NF-κB (Herold, Gabrielli & Vadász, 2013; Bhattacharya & Matthay, 2013). Lidocaine, however, failed to exhibit previously observed properties of membrane and cell stabilization at the level of the alveolo-capillary unit (e.g., elevated EVLWI) via inhibition of apoptosis by attenuating the p38 MAPK pathway (Ma, Yan & He, 2022).

Activated platelets are believed to play a crucial role in the pathogenesis of inflammation, sepsis, and sepsis-associated acute respiratory failure (Kiyonari *et al.*, 2000). Platelet-leukocyte aggregation (PLA), the interaction with leukocytes, has been reported as a potential marker for sepsis and thromboembolism in critically ill patients. Reports suggest that local anesthetics, especially lidocaine, modulate platelet activation and aggregation. *In vitro* and *in vivo* studies have shown that lidocaine reduces inflammatory injury caused by reperfusion, endotoxin-, and hypoxia-induced injury at an early stage, with a stabilization of platelet counts (Huang *et al.*, 2009; Lo *et al.*, 2001; Swanton & Shorten, 2003). One possible mechanism is the inhibition of the ADP-induced P-selection expression for PLA (Huang *et al.*, 2009). In this study, a drop in platelet count associated with sepsis-like changes was observed. Unfortunately, the reported effects of stabilizing platelets and leukocytes were not observed. But both studies are difficult to compare because the dosages used were different. The dosages used by Huang *et al.* (2009) were

clinically relevant for local application but not for intravenous application. The dosage of lidocaine and the observed anti-inflammatory effects appear to be particularly important in all reports.

Several limitations to this study should be considered: (1) 8 h of experimentally induced ARDS only reflect the earliest phase of pathophysiological changes in ARDS. These circumstances are due to local regulations. (2) To reduce confounders in analyzing the results, only one gender was used, which is a non-clinical and unreal scenario. (3) The serum levels of inflammatory markers should have been determined for better comparability of the study results. Further, the serum concentrations of lidocaine, especially in the inhalative group, should have been measured. (4) The statements about the effect on the thrombocytic level can only be used indirectly and to a limited extent. A differentiated thrombocyte examination was not carried out.

CONCLUSION

Unfortunately, the present study did not provide evidence to support the previously reported anti-inflammatory effects of lidocaine in a porcine model of septic ARDS, irrespective of its route of administration (inhalation and intravenous). Future investigations should focus on extending the duration of the study, conducting more detailed anti-inflammatory assessments, and examining different dosages of lidocaine. The potential role of lidocaine as a therapeutic agent for acute lung injury patients remains uncertain.

ACKNOWLEDGEMENTS

The authors thank Mrs. Dagmar Dirvonskis and Mr. Bastian Duenges for support in logistics and laboratory organization. The manuscript was revised and proofread by ChatGPT Feb13 (OpenAI; USA).

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

Erik K. Hartmann is an Academic Editor for PeerJ.

Author Contributions

- René Rissel analyzed the data, prepared figures and/or tables, authored and approved the final draft.
- Christian Moellmann conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Victoria Albertsmeier performed the experiments, prepared figures and/or tables, and approved the final draft.
- Miriam Renz analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

- Robert Ruemmler analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Jens Kamuf performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Erik K. Hartmann conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Alexander Ziebart conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.

Animal Ethics

The following information was supplied relating to ethical approvals (*i.e.*, approving body and any reference numbers):

The State and Institutional Animal Care Committee (Rhineland-Palatinate, Koblenz, Germany) approved the study (ID G16-1-015).

Data Availability

The following information was supplied regarding data availability:

Raw data are available in a [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.15875#supplemental-information>.

REFERENCES

- Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, Le Gall R. 2002. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Medicine* **28**(2):108–121 DOI [10.1007/s00134-001-1143-z](https://doi.org/10.1007/s00134-001-1143-z).
- Ali ZA, El-Mallah RS. 2020. Nebulized lidocaine in COVID-19, an hypothesis. *Medical Hypotheses* **144**(1):109947 DOI [10.1016/j.mehy.2020.109947](https://doi.org/10.1016/j.mehy.2020.109947).
- Beaussier M, Delbos A, Maurice-Szamburski A, Ecoffey C, Mercadal L. 2018. Perioperative use of intravenous lidocaine. *Drugs* **78**(12):1229–1246 DOI [10.1007/s40265-018-0955-x](https://doi.org/10.1007/s40265-018-0955-x).
- Berger C, Rossaint J, Van Aken H, Westphal M, Hahnenkamp K, Zarbock A. 2014. Lidocaine reduces neutrophil recruitment by abolishing chemokine-induced arrest and transendothelial migration in septic patients. *Journal of Immunology* **192**(1):367–376 DOI [10.4049/jimmunol.1301363](https://doi.org/10.4049/jimmunol.1301363).
- Bhattacharya J, Matthay MA. 2013. Regulation and repair of the alveolar-capillary barrier in acute lung injury. *Annual Review of Physiology* **75**(1):593–615 DOI [10.1146/annurev-physiol-030212-183756](https://doi.org/10.1146/annurev-physiol-030212-183756).
- Bos LDJ, Ware LB. 2022. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. *The Lancet* **400**(10358):1145–1156 DOI [10.1016/S0140-6736\(22\)01485-4](https://doi.org/10.1016/S0140-6736(22)01485-4).
- Caracas HCPM, Maciel JVB, Martins PMRS, de Souza MMG, Maia LC. 2009. The use of lidocaine as an anti-inflammatory substance: a systematic review. *Journal of Dentistry* **37**(2):93–97 DOI [10.1016/j.jdent.2008.10.005](https://doi.org/10.1016/j.jdent.2008.10.005).

- Chen LJ, Ding YB, Ma PL, Jiang SH, Li KZ, Li AZ, Li MC, Shi CX, Du J, Zhou HD.** 2018. The protective effect of lidocaine on lipopolysaccharide-induced acute lung injury in rats through NF-κB and p38 MAPK signaling pathway and excessive inflammatory responses. *European Review for Medical and Pharmacological Sciences* 22:2099–2108
DOI 10.26355/EURREV_201804_14743.
- Dunn LK, Durieux ME.** 2017. Perioperative use of intravenous lidocaine. *Anesthesiology* 126(4):729–737 DOI 10.1097/ALN.0000000000001527.
- Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, MacHado FR, McIntyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estessoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Møller M, Iwashyna T, Jacob S, Kleinpell R, Klompaas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M.** 2021. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Critical Care Medicine* 49(11):E1063–E1143
DOI 10.1097/CCM.0000000000005337.
- Hartmann EK, Thomas R, Liu T, Stefaniak J, Ziebart A, Duenges B, Eckle D, Markstaller K, David M.** 2014. TIP peptide inhalation in experimental acute lung injury: effect of repetitive dosage and different synthetic variants. *BMC Anesthesiology* 14(1):42
DOI 10.1186/1471-2253-14-42.
- Herold S, Gabrielli NM, Vadász I.** 2013. Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. *American Journal of Physiology-Lung Cellular and Molecular Physiology* 305(10):L665–L681 DOI 10.1152/ajplung.00232.2013.
- Huang GS, Lin TC, Wang JY, Ku CH, Ho ST, Li CY.** 2009. Lidocaine priming reduces ADP-induced P-selectin expression and platelet-leukocyte aggregation. *Acta Anaesthesiologica Taiwanica: Official Journal of the Taiwan Society of Anesthesiologists* 47(2):56–61
DOI 10.1016/S1875-4597(09)60025-4.
- Jozwiak M, Silva S, Persichini R, Anguel N, Osman D, Richard C, Teboul JL, Monnet X.** 2013. Extravascular lung water is an independent prognostic factor in patients with acute respiratory distress syndrome. *Critical Care Medicine* 41(2):472–480
DOI 10.1097/CCM.0b013e31826ab377.
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG.** 2010. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLOS Biology* 8(6):e1000412 DOI 10.1371/journal.pbio.1000412.
- Kintzel PE, Knol JD, Roe G.** 2019. Intravenous lidocaine administered as twice daily bolus and continuous infusion for intractable cancer pain and wound care pain. *Journal of Palliative Medicine* 22(3):343–347 DOI 10.1089/jpm.2018.0243.
- Kiyonari Y, Nishina K, Mikawa K, Maekawa N, Obara H.** 2000. Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin. *Critical Care Medicine* 28(2):484–489 DOI 10.1097/00003246-200002000-00033.
- Kodama SI, Mikawa K, Nishina K, Maekawa N, Kagawa T, Obara H.** 2000. Lidocaine attenuates sepsis-induced diaphragmatic dysfunction in hamsters. *Critical Care Medicine* 28(7):2475–2479
DOI 10.1097/00003246-200007000-00048.
- Lo B, Hönenmann CW, Kohrs R, Hollmann MW, Polanowska-Grabowska RK, Gear ARL, Durieux ME.** 2001. Local anesthetic actions on thromboxane-induced platelet aggregation. *Anesthesia and Analgesia* 93(5):1240–1245 DOI 10.1097/00000539-200111000-00040.

- Ma X, Yan W, He N.** 2022. Lidocaine attenuates hypoxia/reoxygenation-induced inflammation, apoptosis and ferroptosis in lung epithelial cells by regulating the p38 MAPK pathway. *Molecular Medicine Reports* 25(5):L301 DOI 10.3892/mmr.2022.12666.
- Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, Kuebler WM.** 2011. An official american thoracic society workshop report: features and measurements of experimental acute lung injury in animals. *American Journal of Respiratory Cell and Molecular Biology* 44(5):725–738 DOI 10.1165/rcmb.2009-0210ST.
- Matute-Bello G, Frevert CW, Martin TR.** 2008. Animal models of acute lung injury. *American Journal of Physiology-Lung Cellular and Molecular Physiology* 295(6):L1067 DOI 10.1152/ajplung.90520.2008.
- Romera A, Cebollero Mía, Romero-Gómez B, Carricondo F, Zapatero S, García-Alda Uío, Martín-Albo L, Ortega J, Vara E, Garutti I, Simón C.** 2021. Effect of intravenous lidocaine on inflammatory and apoptotic response of ischemia-reperfusion injury in pigs undergoing lung resection surgery. *BioMed Research International* 2021(12):1–9 DOI 10.1155/2021/6630232.
- Serra MF, Anjos-Valotta EA, Olsen PC, Couto GC, Jurgilas PB, Cotias AC, Pão CR, Ferreira TPT, Arantes ACS, Pires ALA, Cordeiro RSB, Silva PMR, Martins MA.** 2012. Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. *Anesthesiology* 117(3):580–591 DOI 10.1097/ALN.0b013e31826687d5.
- Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC.** 2016. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315(8):801–810 DOI 10.1001/jama.2016.0287.
- Spieth PM, Güldner A, Beda A, Carvalho N, Nowack T, Krause A, Rentzsch I, Suchantke S, Thal SC, Engelhard K, Kasper M, Koch T, Pelosi P, De Abreu MG.** 2012. Comparative effects of proportional assist and variable pressure support ventilation on lung function and damage in experimental lung injury. *Critical Care Medicine* 40(9):2654–2661 DOI 10.1097/CCM.0b013e3182592021.
- Swanton BJ, Shorten GD.** 2003. Anti-inflammatory effects of local anesthetic agents. *International Anesthesiology Clinics* 41(1):1–19 DOI 10.1097/00004311-200341010-00003.
- Thomas R, Liu T, Schad A, Ruemmler R, Kamuf J, Rissel R, Ott T, David M, Hartmann EK, Ziebart A.** 2022. Hyaluronic acid plasma levels during high versus low tidal volume ventilation in a porcine sepsis model. *PeerJ* 9(7):e12649 DOI 10.7717/peerj.12649.
- Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG.** 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. *Intensive Care Medicine* 22(7):707–710 DOI 10.1007/BF01709751.
- Zhang Z, Zhou J, Liao C, Li X, Liu M, Song D, Jiang X.** 2017. RAGE deficiency attenuates the protective effect of Lidocaine against sepsis-induced acute lung injury. *Inflammation* 40(2):601–611 DOI 10.1007/s10753-016-0507-z.
- Ziebart A, Hartmann EK, Thomas R, Liu T, Duenges B, Schad A, Bodenstein M, Thal SC, David M.** 2014. Low tidal volume pressure support versus controlled ventilation in early experimental sepsis in pigs. *Respiratory Research* 15(1):101 DOI 10.1186/s12931-014-0101-6.